Marisa Wexler, MS,  senior science writer—

After starting treatment with Trikafta, people with cystic fibrosis (CF) tend to have less need for inhaled mucus-clearing therapies and antibiotics, according to a new analysis of data from a real-world study. Moreover, the reduced need for other medication while on Trikafta was found to continue over the…

People with cystic fibrosis (CF) who have certain lung structure abnormalities — ones visible on CT scans — are more likely than those with other issues also seen via imaging to experience improvements in lung function after starting treatment with Trikafta. That’s according to the results of a new analysis…

The U.S. Food and Drug Administration (FDA) has approved a new generic form of inhaled tobramycin, an antibiotic that’s used to treat bacterial lung infections in people with cystic fibrosis (CF). The newly approved therapy, tobramycin inhalation solution, will be sold by The Ritedose Corporation through its…

Sionna Therapeutics has launched a clinical trial to test its experimental therapy SION-719 in combination with Trikafta (elexacaftor/tezacaftor/ivacaftor), which is currently the standard-of-care treatment for cystic fibrosis (CF). According to a company press release, the Phase 2a study (NCT07108153) will enroll adults with CF who…

ARCT-032, Arcturus Therapeutics’ experimental inhaled therapy for cystic fibrosis (CF), has been well tolerated so far in a clinical trial. Early imaging data also suggest it may help clear mucus from the lungs, according to interim results announced by the company. “These findings suggest that ARCT-032 may be…

Despite a recent hold by the U.S. Food and Drug Administration (FDA) on a BX004 clinical trial in the U.S., the experimental cystic fibrosis (CF) lung infection treatment is still advancing in Europe. According to BX004’s developer Biomx, top-line results are expected in early 2026. “Patient enrollment and…

Enrollment has finished in a clinical trial testing the experimental therapy CMTX-101, which is designed to help clear out bacterial lung infections in people with cystic fibrosis (CF) and other diseases. Top-line results from the Phase 1b/2a study (NCT06159725) are expected to be announced in the first quarter…

The Cystic Fibrosis Foundation is making a new investment of up to $11 million in 4D Molecular Therapeutics (4DMT) to support the development of 4D-710, the company’s inhaled gene therapy for cystic fibrosis (CF) that is currently in clinical development. The funding, which builds on earlier support,…

The experimental anti-inflammatory therapy brensocatib was generally well tolerated in adults with cystic fibrosis (CF), according to data from a small clinical trial aimed at aiding the design of future studies of the therapy. Brensocatib’s pharmacological profile in CF patients is similar to its profile in people without CF,…

The Cystic Fibrosis Foundation has made an additional $3 million investment in Recode Therapeutics to support clinical development of RCT2100, an investigational therapy for cystic fibrosis (CF) that is currently being tested in patients who cannot take CFTR modulators. The CF Foundation had previously invested $15 million…